on MIG CAPITAL AG
MIG Capital Partners with CoreMedic for Series B Extension Funding
MIG Capital AG and CoreMedic GmbH have announced new funding for CoreMedic’s Series B extension. This round supports the ChordArt transcatheter mitral valve repair device, a minimally invasive alternative to traditional surgery. CoreMedic aims to leverage this funding to complete its First-in-human study, crucial for advancing clinical development.
MIG Capital, a leading venture firm, joins an international syndicate of medtech investors. Matthias Guth from MIG Capital highlights CoreMedic’s innovative approach to cardiovascular treatments. ChordArt addresses Mitral Valve Regurgitation, a condition affecting over 24 million people globally. Its minimally invasive technology offers hope to patients unable to undergo open-heart surgery.
The new investments will enable CoreMedic to expand its clinical programs globally. This partnership marks a significant milestone in the company's development, facilitating progress towards broader accessibility of innovative heart valve repair options.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MIG CAPITAL AG news